Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes (anti IL-1)

This study has been completed.
Information provided by (Responsible Party):
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Identifier:
First received: July 24, 2009
Last updated: May 28, 2013
Last verified: May 2013